本帖最后由 老马 于 2012-1-13 21:20 编辑 " f# F- [7 D( A0 o4 P- p5 t/ \$ |
) R& k( G y* n' G% v! V- i/ r1 Z爱必妥和阿瓦斯丁的比较! E2 }% V* b5 f
9 N3 G6 R' q+ N9 Y. Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/ {+ ]3 g& c. J( I$ G( s" O
) N2 H0 Q. d' `" x
1 i% s: A6 `+ [6 ?http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 _, ?) K1 \) T# T5 C* z* c+ n==================================================0 U+ i( s6 @" P _, R) f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 O$ y* g& C5 \
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. r' C: g" o, L' c3 ^5 T. H
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.# u) A! v. X K, W8 ?7 z$ b1 T
|
显身卡
